Zydus Cadila gets USFDA approval for Colesevelam Hydrochloride Tablets

Zydus Cadila has received the final approval from the United States Federation of Drug Authority (USFDA) to market Colesevelam Hydrochloride Tablets, (US RLD - Welchol), 625 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

This medication is used along with a proper diet and exercise, to lower cholesterol in people with high levels of cholesterol in the blood. Lowering cholesterol decreases the risk of heart disease and helps preventing strokes and heart attacks.

The group now has 273 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

Last month, the company had also received the USFDA approval A to market Clobetasol Propionate Lotion, (US RLD - Clobex Lotion), 0.05%. It will be manufactured at the group's topical manufacturing facility at Ahmedabad.

This medication is used to treat a variety of skin conditions like eczema, psoriasis, dermatitis, allergies and rash. Clobctasol reduces the swelling, itching and redness that can occur in these types of conditions.

On Wednesday, the share of Cadila Healthcare opened at Rs. 229.00. During the day, it surged by 3.9 per cent to hit intraday high of Rs. 237.25.